Product Description
AZD-2936 is being developed by AstraZeneca for the treatment of solid tumors. (Sourced from: https://www.astrazeneca.com/our-therapy-areas/pipeline.html)
Mechanisms of Action: PD-1 Inhibitor, TIGIT Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Moldova, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 66
Recent & Upcoming Milestones
- Clinical Outcomes Reported - AstraZeneca presented P1 Biliary Tract Cancer results on 2026-05-30 for Rilvegostomig
- Clinical Outcomes Reported - AstraZeneca presented P2 Breast Cancer results on 2026-06-01 for Rilvegostomig
- Clinical Outcomes Reported - Compugen presented P2 Gastrointestinal Cancer results on 2026-05-29 for Rilvegostomig
Highest Development Phases
Phase 3: Adenocarcinoma|Bile Duct Cancer|Biliary Tract Cancer|Cholangiocarcinoma|Endometrial Cancer|Esophageal Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Klatskin Tumor|Lung Cancer|Muscle Cancer|Non-Small-Cell Lung Cancer|Skin Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Head and Neck Cancer|Lewy Body Disease|Oncology Solid Tumor Unspecified|Parkinson's Disease
Phase 1: Lymphoma|Melanoma|Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04541108 |
PBI-MST-01 | P1 |
Active, not recruiting |
Head and Neck Cancer|Melanoma|Squamous Cell Carcinoma|Lymphoma|Sarcoma |
2031-12-01 |
2026-05-23 |
||
NCT06366451 |
MST01-AZN-05 | P1 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2026-03-25 |
2026-06-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
jRCT2051250123 |
jRCT2051250123 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2030-01-08 |
|||
2022-502317-29-00 |
D7987C00001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-11-25 |
2025-05-02 |
Treatments |
|
NCT05775159 |
GEMINI-Hepatobiliary | P2 |
Recruiting |
Biliary Tract Cancer|Hepatocellular Carcinoma |
2026-10-27 |
12% |
2025-11-14 |
|
NCT04995523 |
ARTEMIDE-01 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Parkinson's Disease|Lewy Body Disease |
2026-08-28 |
12% |
2026-03-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2024-510977-27-00 |
D7986C00001 | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2026-03-31 |
12% |
2025-05-02 |
Treatments |
2024-517780-24-00 |
D702GC00001 | P3 |
Not yet recruiting |
Lung Cancer |
2031-01-25 |
64% |
||
2023-506054-20-00 |
D7025C00001 | P3 |
Recruiting |
Muscle Cancer|Adenocarcinoma|Cholangiocarcinoma|Biliary Tract Cancer|Gallbladder Cancer |
2030-09-30 |
80% |
2025-05-02 |
Treatments |
NCT06989112 |
DE-01 | P3 |
Recruiting |
Endometrial Cancer |
2029-01-19 |
83% |
2025-05-28 |
Primary Endpoints |
NCT06109779 |
ARTEMIDE-Biliary01 | P3 |
Active, not recruiting |
Biliary Tract Cancer|Skin Cancer|Klatskin Tumor|Cholangiocarcinoma|Bile Duct Cancer|Gallbladder Cancer |
2029-01-02 |
80% |
2026-03-05 |
Patient Enrollment|Primary Endpoints|Trial Status |
jRCT2031240095 |
jRCT2031240095 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-06-30 |
|||
2023-505077-32-00 |
D7632C00001 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-05-24 |
80% |
2025-05-02 |
Treatments |
jRCT2061240062 |
jRCT2061240062 | P3 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2035-03-31 |
|||
2024-512195-35-00 |
D926TC00001 | P3 |
Not yet recruiting |
Adenocarcinoma|Non-Small-Cell Lung Cancer |
2035-02-01 |
9% |
2025-05-02 |
Treatments |
jRCT2051250117 |
jRCT2051250117 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2032-01-31 |
|||
2024-519787-40-00 |
D9803C00001 | P3 |
Not yet recruiting |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2031-10-27 |
54% |
||
jRCT2031250781 |
jRCT2031250781 | P3 |
Recruiting |
Gastrointestinal Cancer|Esophageal Cancer |
2031-06-30 |
|||
jRCT2011250015 |
jRCT2011250015 | P3 |
Recruiting |
Endometrial Cancer |
2031-03-31 |
|||
jRCT2031250011 |
jRCT2031250011 | P3 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2031-02-28 |
|||
2023-508056-19-00 |
DESTINYEndometrial01 | P3 |
Not yet recruiting |
Endometrial Cancer |
2031-02-24 |
83% |
||
2023-508852-21-00 |
D9077C00001 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-12-10 |
73% |
2025-05-02 |
Treatments |
NCT05061550 |
NeoCOAST-2 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-05-28 |
73% |
2026-03-07 |
|
2024-512583-57-00 |
D702AC00001 | P3 |
Not yet recruiting |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2030-12-09 |
84% |
||
jRCT2031230509 |
jRCT2031230509 | P3 |
Not yet recruiting |
Biliary Tract Cancer |
2030-09-30 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/09/2026 |
News Article |
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference |
|
04/02/2026 |
News Article |
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer |
|
02/12/2026 |
News Article |
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors |
|
12/17/2025 |
News Article |
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million |